H.C. Wainwright Reiterates a Buy Rating on Citius Pharmaceuticals (CTXR)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Citius Pharmaceuticals (CTXR), with a price target of $4.00. The company’s shares closed last Friday at $2.03.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 36.6% and a 41.4% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Tenax Therapeutics, and Can-Fite BioPharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Citius Pharmaceuticals with a $5.00 average price target, representing a 147.5% upside. In a report issued on February 18, Dawson James also maintained a Buy rating on the stock with a $6.00 price target.

See today’s analyst top recommended stocks >>

Based on Citius Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.15 million. In comparison, last year the company had a GAAP net loss of $4.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts